Author:
Carreira Dominic S.,Garden Steven,Huffman Allison,Ueland Thomas
Abstract
Public interest in the analgesic potential of cannabinoids has grown, but there is no consensus regarding orthopedic applications. Available evidence was identified for cannabinoid use in arthritis, neuropathic pain, fibromyalgia, multiple sclerosis, and postoperative pain. Extracted information included the risks of preoperative use, associations with opioid dependence, and surgical complications. There is limited evidence for therapeutic benefit of cannabinoids in rheumatoid arthritis and fibromyalgia. Cannabinoids are not indicated for postoperative pain. Preoperative unregulated use has been linked with postoperative opioid dependence. Cannabinoids may be considered a second- or third-line treatment for analgesia for some orthopedic pathologies. [
Orthopedics
. 2022;45(4):e183–e189.]
Subject
Orthopedics and Sports Medicine,Surgery
Reference64 articles.
1. Osteoarthritis prevalence and modifiable factors: a population study
2. Crombie IK, Croft PR, Linton SJ, Leresche L, Korff MV. Epidemiology of Pain: A Report of the Task Force on Epidemiology. IASP Press; 1999.
3. Systematic review of persistent pain and psychological outcomes following traumatic musculoskeletal injury
4. Opioids should be last resort to treat chronic pain, says draft CDC guideline
5. U.S. Food and Drug Administration. FDA regulation of cannabis and cannabis-derived products: Q&A. U.S. Food and Drug Administration. Accessed February 8 2022. https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献